Publication Results

Generate Report

Add publications by marking their checkboxes, or

Pancreatic Cancer Chemoprevention Translational Workshop: Meeting Report.

Miller MS,  Allen P,  Brentnall TA,  Goggins M,  Hruban RH,  Petersen GM,  Rao CV,  Whitcomb DC,  Brand RE,  Chari ST,  Klein AP,  Lubman DM,  Rhim AD,  Simeone DM,  Wolpin BM,  Umar A,  Srivastava S,  Steele VE,  Rinaudo JA
Pancreas 2016 Sep;45(8):1080-91
PubMed ID: 27518363
PMC ID: PMC4988336
Groups or Programs: Chemopreventive Agent DevelopmentCancer BiomarkersGastrointestinal and Other Cancers

Introduction: Cancer chemoprevention and its context.

Dunn BK,  Umar A,  Richmond E
Semin Oncol 2016 Feb;43(1):19-21
PubMed ID: 26970121
PMC ID: PMC5166611
Groups or Programs: Chemopreventive Agent DevelopmentGastrointestinal and Other Cancers

An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis.

Lynch PM,  Burke CA,  Phillips R,  Morris JS,  Slack R,  Wang X,  Liu J,  Patterson S,  Sinicrope FA,  Rodriguez-Bigas MA,  Half E,  Bulow S,  Latchford A,  Clark S,  Ross WA,  Malone B,  Hasson H,  Richmond E,  Hawk E
Gut 2016 Feb;65(2):286-95
PubMed ID: 25792707
PMC ID: not available
Groups or Programs: Gastrointestinal and Other Cancers

Mechanisms of esophageal adenocarcinoma formation and approaches to chemopreventive intervention.

Richmond E,  Umar A
Semin Oncol 2016 Feb;43(1):78-85
PubMed ID: 26970126
PMC ID: not available
Groups or Programs: Gastrointestinal and Other Cancers

Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention.

Umar A,  Steele VE,  Menter DG,  Hawk ET
Semin Oncol 2016 Feb;43(1):65-77
PubMed ID: 26970125
PMC ID: not available
Groups or Programs: Chemopreventive Agent DevelopmentGastrointestinal and Other Cancers

Hereditary cancer syndromes as model systems for chemopreventive agent development.

Walcott FL,  Patel J,  Lubet R,  Rodriguez L,  Calzone KA
Semin Oncol 2016 Feb;43(1):134-145
PubMed ID: 26970132
PMC ID: not available
Groups or Programs: Chemopreventive Agent DevelopmentGastrointestinal and Other Cancers

Immunologic approaches to cancer prevention-current status, challenges, and future perspectives.

Wojtowicz ME,  Dunn BK,  Umar A
Semin Oncol 2016 Feb;43(1):161-172
PubMed ID: 26970135
PMC ID: not available
Groups or Programs: Chemopreventive Agent DevelopmentGastrointestinal and Other CancersLung and Upper Aerodigestive Cancer

A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP.

Morgan TR,  Osann K,  Bottiglieri T,  Pimstone N,  Hoefs JC,  Hu KQ,  Hassanein T,  Boyer TD,  Kong L,  Chen WP,  Richmond E,  Gonzalez R,  Rodriguez LM,  Meyskens FL
Cancer Prev Res (Phila) 2015 Sep;8(9):864-72
PubMed ID: 26130251
PMC ID: PMC4560676
Groups or Programs: Gastrointestinal and Other CancersLung and Upper Aerodigestive Cancer

Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus.

Chak A,  Buttar NS,  Foster NR,  Seisler DK,  Marcon NE,  Schoen R,  Cruz-Correa MR,  Falk GW,  Sharma P,  Hur C,  Katzka DA,  Rodriguez LM,  Richmond E,  Sharma AN,  Smyrk TC,  Mandrekar SJ,  Limburg PJ,  Cancer Prevention Network
Clin Gastroenterol Hepatol 2015 Apr;13(4):665-4
PubMed ID: 25218668
PMC ID: PMC4362887
Groups or Programs: Early DetectionGastrointestinal and Other Cancers

Colorectal cancer prevention and fishful thinking.

Umar A,  Richmond E,  Kramer BS
J Natl Cancer Inst 2015 Apr;107(4)
PubMed ID: 25810493
PMC ID: not available
Groups or Programs: Gastrointestinal and Other Cancers ;  Office of the Director

A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum.

Gillen DL,  Meyskens FL,  Morgan TR,  Zell JA,  Carroll R,  Benya R,  Chen WP,  Mo A,  Tucker C,  Bhattacharya A,  Huang Z,  Arcilla M,  Wong V,  Chung J,  Gonzalez R,  Rodriguez LM,  Szabo E,  Rosenberg DW,  Lipkin SM
Cancer Prev Res (Phila) 2015 Mar;8(3):222-30
PubMed ID: 25604134
PMC ID: PMC4355051
Groups or Programs: Gastrointestinal and Other CancersLung and Upper Aerodigestive Cancer

Estimates of benefits and harms of prophylactic use of aspirin in the general population.

Cuzick J,  Thorat MA,  Bosetti C,  Brown PH,  Burn J,  Cook NR,  Ford LG,  Jacobs EJ,  Jankowski JA,  La Vecchia C,  Law M,  Meyskens F,  Rothwell PM,  Senn HJ,  Umar A
Ann Oncol 2015 Jan;26(1):47-57
PubMed ID: 25096604
PMC ID: PMC4269341
Groups or Programs: Gastrointestinal and Other CancersLung and Upper Aerodigestive Cancer ;  Office of the Director

Barrett's Esophagus Translational Research Network (BETRNet): the pivotal role of multi-institutional collaboration in esophageal adenocarcinoma research.

Abrams JA,  Appelman HD,  Beer DG,  Berry LD,  Chak A,  Falk GW,  Fitzgerald RC,  Ginsberg GG,  Grady WM,  Joshi BP,  Lynch JP,  Markowitz S,  Richmond ES,  Rustgi AK,  Seibel EJ,  Shaheen NJ,  Shyr Y,  Umar A,  Wang KK,  Wang TC,  Wang TD,  Yassin R
Gastroenterology 2014 Jun;146(7):1586-90
PubMed ID: 24768332
PMC ID: PMC4224108
Groups or Programs: Gastrointestinal and Other Cancers

A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus.

Falk GW,  Buttar NS,  Foster NR,  Ziegler KL,  Demars CJ,  Romero Y,  Marcon NE,  Schnell T,  Corley DA,  Sharma P,  Cruz-Correa MR,  Hur C,  Fleischer DE,  Chak A,  Devault KR,  Weinberg DS,  Della'Zanna G,  Richmond E,  Smyrk TC,  Mandrekar SJ,  Limburg PJ,  Cancer Prevention Network
Gastroenterology 2012 Oct;143(4):917-26.e1
PubMed ID: 22796132
PMC ID: PMC3458136
Groups or Programs: Gastrointestinal and Other CancersPhase 0/I/II Trials

Is 15-LOX-1 a tumor suppressor?

Umar A
J Natl Cancer Inst 2012 May 2;104(9):645-7
PubMed ID: 22472307
PMC ID: not available
Groups or Programs: Gastrointestinal and Other Cancers

Barrett's esophagus: natural history.

Appelman HD,  Umar A,  Orlando RC,  Sontag SJ,  Nandurkar S,  El-Zimaity H,  Lanas A,  Parise P,  Lambert R,  Shields HM
Ann N Y Acad Sci 2011 Sep;1232:292-308
PubMed ID: 21950819
PMC ID: not available
Groups or Programs: Gastrointestinal and Other Cancers

Peto's Paradox: evolution's prescription for cancer prevention.

Caulin AF,  Maley CC
Trends Ecol Evol 2011 Apr;26(4):175-82
PubMed ID: 21296451
PMC ID: PMC3060950
Groups or Programs: Gastrointestinal and Other Cancers

Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms.

Lipkin S,  Lee J,  Imagawa D,  Hewitt SM,  Tucker C,  Zell JA,  Wong V,  Garcia A,  Gonzalez R,  Della Zanna G,  Richmond E,  Rodriguez LM,  Bigg M,  Schnoll-Sussmans F,  Meyskens F
Cancer Prev Res (Phila) 2011 Apr;4(4):512-3
PubMed ID: 21464031
PMC ID: PMC4492452
Groups or Programs: Gastrointestinal and Other CancersPhase 0/I/II Trials

Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia.

Carroll RE,  Benya RV,  Turgeon DK,  Vareed S,  Neuman M,  Rodriguez L,  Kakarala M,  Carpenter PM,  McLaren C,  Meyskens FL Jr,  Brenner DE
Cancer Prev Res (Phila) 2011 Mar;4(3):354-64
PubMed ID: 21372035
PMC ID: PMC4136551
Groups or Programs: Gastrointestinal and Other CancersPhase 0/I/II Trials

Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention.

Limburg PJ,  Mahoney MR,  Ziegler KL,  Sontag SJ,  Schoen RE,  Benya R,  Lawson MJ,  Weinberg DS,  Stoffel E,  Chiorean M,  Heigh R,  Levine J,  Della'Zanna G,  Rodriguez L,  Richmond E,  Gostout C,  Mandrekar SJ,  Smyrk TC,  Cancer Prevention Network
Cancer Prev Res (Phila) 2011 Feb;4(2):259-69
PubMed ID: 21209397
PMC ID: PMC3046804
Groups or Programs: Gastrointestinal and Other CancersPhase 0/I/II Trials

Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.

Elmets CA,  Viner JL,  Pentland AP,  Cantrell W,  Lin HY,  Bailey H,  Kang S,  Linden KG,  Heffernan M,  Duvic M,  Richmond E,  Elewski BE,  Umar A,  Bell W,  Gordon GB
J Natl Cancer Inst 2010 Dec 15;102(24):1835-44
PubMed ID: 21115882
PMC ID: PMC3001966
Groups or Programs: Gastrointestinal and Other Cancers

A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma.

Merlo LM,  Shah NA,  Li X,  Blount PL,  Vaughan TL,  Reid BJ,  Maley CC
Cancer Prev Res (Phila) 2010 Nov;3(11):1388-97
PubMed ID: 20947487
PMC ID: PMC3004782
Groups or Programs: Gastrointestinal and Other Cancers

Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma.

Thompson PA,  Wertheim BC,  Zell JA,  Chen WP,  McLaren CE,  LaFleur BJ,  Meyskens FL,  Gerner EW
Gastroenterology 2010 Sep;139(3):797-805, 805.e1
PubMed ID: 20538001
PMC ID: PMC3399666
Groups or Programs: Gastrointestinal and Other Cancers

Conducting chemoprevention clinical trials: challenges and solutions.

Richmond E,  O'Mara A
Semin Oncol 2010 Aug;37(4):402-6
PubMed ID: 20816509
PMC ID: not available
Groups or Programs: Community Oncology and Prevention TrialsGastrointestinal and Other Cancers

Further thoughts on preclinical animal models for cancer prevention: when is it best to start treatment? What are potential histopathologic endpoints?

Umar A,  Della'Zanna G,  Lubet R
Semin Oncol 2010 Aug;37(4):339-44
PubMed ID: 20816504
PMC ID: not available
Groups or Programs: Gastrointestinal and Other CancersChemopreventive Agent Development

One year recurrence of aberrant crypt foci.

Pinsky PF,  Fleshman J,  Mutch M,  Rall C,  Charabaty A,  Seligson D,  Dry S,  Umar A,  Schoen RE
Cancer Prev Res (Phila) 2010 Jul;3(7):839-43
PubMed ID: 20570885
PMC ID: PMC2900400
Groups or Programs: Gastrointestinal and Other CancersEarly DetectionPLCO Cancer Screening Trial

The safety and efficacy of celecoxib in children with familial adenomatous polyposis.

Lynch PM,  Ayers GD,  Hawk E,  Richmond E,  Eagle C,  Woloj M,  Church J,  Hasson H,  Patterson S,  Half E,  Burke CA
Am J Gastroenterol 2010 Jun;105(6):1437-43
PubMed ID: 20234350
PMC ID: not available
Groups or Programs: Gastrointestinal and Other Cancers

Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial.

Bertagnolli MM,  Hsu M,  Hawk ET,  Eagle CJ,  Zauber AG,  Adenoma Prevention with Celecoxib (APC) Study Investigators
Cancer Prev Res (Phila) 2010 May;3(5):588-96
PubMed ID: 20403998
PMC ID: PMC2990920
Groups or Programs: Gastrointestinal and Other CancersBiometry

The role of genetic diversity in cancer.

Merlo LM,  Maley CC
J Clin Invest 2010 Feb;120(2):401-3
PubMed ID: 20101092
PMC ID: PMC2810093
Groups or Programs: Gastrointestinal and Other Cancers

A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer.

Bailey HH,  Kim K,  Verma AK,  Sielaff K,  Larson PO,  Snow S,  Lenaghan T,  Viner JL,  Douglas J,  Dreckschmidt NE,  Hamielec M,  Pomplun M,  Sharata HH,  Puchalsky D,  Berg ER,  Havighurst TC,  Carbone PP
Cancer Prev Res (Phila) 2010 Jan;3(1):35-47
PubMed ID: 20051371
PMC ID: PMC2804946
Groups or Programs: Gastrointestinal and Other Cancers

A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Dunn BK,  Richmond ES,  Minasian LM,  Ryan AM,  Ford LG
Nutr Cancer 2010;62(7):896-918
PubMed ID: 20924966
PMC ID: not available
Groups or Programs: Gastrointestinal and Other CancersChemopreventive Agent Development ;  Community Clinical Oncology Program (CCOP) ;  Prostate and Urologic CancerCommunity Oncology and Prevention Trials
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Stool methylation-specific polymerase chain reaction assay for the detection of colorectal neoplasia in Korean patients.

Baek YH,  Chang E,  Kim YJ,  Kim BK,  Sohn JH,  Park DI
Dis Colon Rectum 2009 Aug;52(8):1452-63
PubMed ID: 19617759
PMC ID: not available
Groups or Programs: Gastrointestinal and Other Cancers

Alarming colorectal cancer incidence trends: a case for early detection and prevention.

Umar A,  Greenwald P
Cancer Epidemiol Biomarkers Prev 2009 Jun;18(6):1672-3
PubMed ID: 19505897
PMC ID: not available
Groups or Programs: Gastrointestinal and Other Cancers

A multicenter study of prevalence and risk factors for aberrant crypt foci.

Mutch MG,  Schoen RE,  Fleshman JW,  Rall CJ,  Dry S,  Seligson D,  Charabaty A,  Chia D,  Umar A,  Viner J,  Hawk E,  Pinsky PF
Clin Gastroenterol Hepatol 2009 May;7(5):568-74
PubMed ID: 19418605
PMC ID: not available
Groups or Programs: Gastrointestinal and Other CancersEarly DetectionPLCO Cancer Screening Trial

Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.

Bertagnolli MM,  Eagle CJ,  Zauber AG,  Redston M,  Breazna A,  Kim K,  Tang J,  Rosenstein RB,  Umar A,  Bagheri D,  Collins NT,  Burn J,  Chung DC,  Dewar T,  Foley TR,  Hoffman N,  Macrae F,  Pruitt RE,  Saltzman JR,  Salzberg B,  Sylwestrowicz T,  Hawk ET,  Adenoma Prevention with Celecoxib Study Investigators
Cancer Prev Res (Phila) 2009 Apr;2(4):310-21
PubMed ID: 19336730
PMC ID: PMC2976587
Groups or Programs: Gastrointestinal and Other CancersBiometry

Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas.

Zell JA,  Pelot D,  Chen WP,  McLaren CE,  Gerner EW,  Meyskens FL
Cancer Prev Res (Phila) 2009 Mar;2(3):209-12
PubMed ID: 19258540
PMC ID: PMC2739681
Groups or Programs: Gastrointestinal and Other Cancers

Introduction: diet, epigenetic events and cancer prevention.

Ross SA,  Dwyer J,  Umar A,  Kagan J,  Verma M,  Van Bemmel DM,  Dunn BK
Nutr Rev 2008 Aug;66 Suppl 1:S1-6
PubMed ID: 18673478
PMC ID: PMC2547124
Groups or Programs: Gastrointestinal and Other Cancers

Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.

Meyskens FL Jr,  McLaren CE,  Pelot D,  Fujikawa-Brooks S,  Carpenter PM,  Hawk E,  Kelloff G,  Lawson MJ,  Kidao J,  McCracken J,  Albers CG,  Ahnen DJ,  Turgeon DK,  Goldschmid S,  Lance P,  Hagedorn CH,  Gillen DL,  Gerner EW
Cancer Prev Res (Phila) 2008 Jun;1(1):32-8
PubMed ID: 18841250
PMC ID: PMC2562024
Groups or Programs: Gastrointestinal and Other Cancers

15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation.

Zuo X,  Shen L,  Issa JP,  Moy O,  Morris JS,  Lippman SM,  Shureiqi I
FASEB J 2008 Jun;22(6):1981-92
PubMed ID: 18198215
PMC ID: PMC2410033
Groups or Programs: Gastrointestinal and Other Cancers

Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features.

Sato F,  Jin Z,  Schulmann K,  Wang J,  Greenwald BD,  Ito T,  Kan T,  Hamilton JP,  Yang J,  Paun B,  David S,  Olaru A,  Cheng Y,  Mori Y,  Abraham JM,  Yfantis HG,  Wu TT,  Fredericksen MB,  Wang KK,  Canto M,  Romero Y,  Feng Z,  Meltzer SJ
PLoS One 2008 Apr 2;3(4):e1890
PubMed ID: 18382671
PMC ID: PMC2270339
Groups or Programs: Gastrointestinal and Other Cancers

Leptin and the risk of Barrett's oesophagus.

Kendall BJ,  Macdonald GA,  Hayward NK,  Prins JB,  Brown I,  Walker N,  Pandeya N,  Green AC,  Webb PM,  Whiteman DC,  Study of Digestive Health
Gut 2008 Apr;57(4):448-54
PubMed ID: 18178609
PMC ID: not available
Groups or Programs: Gastrointestinal and Other Cancers

Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma.

Larghi A,  Lightdale CJ,  Ross AS,  Fedi P,  Hart J,  Rotterdam H,  Noffsinger A,  Memeo L,  Bhagat G,  Waxman I
Endoscopy 2007 Dec;39(12):1086-91
PubMed ID: 17701854
PMC ID: not available
Groups or Programs: Gastrointestinal and Other Cancers

Leukocyte telomere length predicts cancer risk in Barrett's esophagus.

Risques RA,  Vaughan TL,  Li X,  Odze RD,  Blount PL,  Ayub K,  Gallaher JL,  Reid BJ,  Rabinovitch PS
Cancer Epidemiol Biomarkers Prev 2007 Dec;16(12):2649-55
PubMed ID: 18086770
PMC ID: not available
Groups or Programs: Gastrointestinal and Other Cancers

Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia.

Overholt BF,  Wang KK,  Burdick JS,  Lightdale CJ,  Kimmey M,  Nava HR,  Sivak MV Jr,  Nishioka N,  Barr H,  Marcon N,  Pedrosa M,  Bronner MP,  Grace M,  Depot M,  International Photodynamic Group for High-Grade Dysplasia in Barrett's Esophagus
Gastrointest Endosc 2007 Sep;66(3):460-8
PubMed ID: 17643436
PMC ID: not available
Groups or Programs: Gastrointestinal and Other Cancers

Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention.

Gerner EW,  Meyskens FL Jr,  Goldschmid S,  Lance P,  Pelot D
Amino Acids 2007 Aug;33(2):189-95
PubMed ID: 17396214
PMC ID: not available
Groups or Programs: Gastrointestinal and Other Cancers

Allelic losses at genomic instability-associated loci in villous adenomas and adjacent colorectal cancers.

Brenner BM,  Stoler DL,  Rodriguez L,  Karpenko MJ,  Swede H,  Petrelli NJ,  Anderson GR
Cancer Genet Cytogenet 2007 Apr 1;174(1):9-15
PubMed ID: 17350461
PMC ID: PMC1855249
Groups or Programs: Gastrointestinal and Other Cancers

The importance of identifying high risk patients in a general screening colonoscopy population: Results from the national colonoscopy study pedigree analysis

Stillman JS,  Kauff N,  Close G Georgia,  Zauber AG Ann,  Winawer SJ
Gastroenterology 2007 Apr;132(4):A625-A625 Suppl 2
PubMed ID: not available
PMC ID: not available
Groups or Programs: Gastrointestinal and Other Cancers

Modulation of aflatoxin toxicity and biomarkers by lycopene in F344 rats.

Tang L,  Guan H,  Ding X,  Wang JS
Toxicol Appl Pharmacol 2007 Feb 15;219(1):10-7
PubMed ID: 17229449
PMC ID: not available
Groups or Programs: Gastrointestinal and Other Cancers

NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.

Galipeau PC,  Li X,  Blount PL,  Maley CC,  Sanchez CA,  Odze RD,  Ayub K,  Rabinovitch PS,  Vaughan TL,  Reid BJ
PLoS Med 2007 Feb;4(2):e67
PubMed ID: 17326708
PMC ID: PMC1808095
Groups or Programs: Gastrointestinal and Other Cancers

Colorectal Cancer Prevention: Diet, Drugs, or Nothing

Umar A,  Richmond E,  Griebel DJ
Current Colorectal Cancer Reports 2007;3(1):16-23
PubMed ID: not available
PMC ID: not available
Groups or Programs: Gastrointestinal and Other Cancers